About Viking Therapeutics, Inc. - Common Stock (VKTX)
Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company is engaged in advancing a portfolio of drug candidates aimed at addressing diseases with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH) and obesity. Viking’s approach leverages proprietary drug development technologies to design and optimize novel therapeutic compounds, with an emphasis on safety and efficacy. Through its research and clinical trials, the company aims to bring transformative treatments to market that can improve patient outcomes and enhance quality of life. Read More
A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.
It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.
Viking Therapeutics (NASDAQ:VKTX) reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much of their initial weight loss after transitioning from weekly treatment to every-other-week or mont
The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.
Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose.
Speaking at the Morgan Stanley Global Healthcare Conference, Pr
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
